• Publications
  • Influence
Therapeutic drug monitoring of asparaginase in the ALL‐BFM 2000 protocol between 2000 and 2007
On a voluntary basis therapeutic drug monitoring (TDM) was implemented in the ALL‐BFM 2000 protocol for the three currently used asparaginase (ASNase) preparations (first line: native Escherichia
Plasma Concentrations of Posaconazole Administered via Nasogastric Tube in Patients in a Surgical Intensive Care Unit
TLDR
Plasma posaconazole levels in surgical intensive care unit (SICU) patients were measured and a predictive population pharmacokinetics model was tried to develop, showing SICU patients showed lower plasma drug concentrations, a higher apparent clearance, and a higher volume of distribution than those in hematology patients.
Population Pharmacokinetics of Native Escherichia Coli Asparaginase
TLDR
The model was able to describe asparaginase activity of different dosages in the ALL-BFM protocol and provides further evidence for bioequivalence between ASNase medac™ and a new recombinant asparaginease preparation.
Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. colil-asparaginase preparation (MC0609) in Beagle dog
TLDR
The new pegylated recombinant l-asparaginase preparation MC0609 revealed striking differences in PK/PD properties compared with Oncaspar® in rat and dog.
Population Pharmacokinetic of Native Escherichia Coli Asparaginase.
TLDR
This PopPK analysis provides the first step in the development of a PopPK model for ASNase and shows face validity of the model could be demonstrated and will be confirmed with an independent dataset.